Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | Using MatchMiner to improve clinical trial enrolment

Harry Klein • 10 Apr 2022
AACR 2022
General

Harry Klein, PhD, Dana Farber Cancer Institute, Boston, MA, explains how the MatchMiner platform from Dana-Farber Cancer Institute hopes to improve clinical trial enrolment. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.

More from Harry Klein

1:29
MatchMiner: A new method of matching patients to precision medicine trials
Harry Klein • 10 Apr 2022

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals